August 25, 1998Circulation
Activation of Platelets in Platelet-Rich Plasma by Rotablation Is Speed-Dependent and Can Be Inhibited by Abciximab (c7E3 Fab; ReoPro)
Why the study?
Does abciximab reduce rotablation-induced platelet aggregation in platelet-rich plasma from healthy volunteers?
Population
Platelet-rich plasma (PRP) prepared from 28 healthy human volunteers
Comparison
Preincubation with abciximab (c7E3 Fab, anti-GP… vs No antibody treatment or preincubation with 6D1…
Design
Preclinical
Authors
Discussion
Loading...
Member takes
Implication
Abciximab inhibits rotablation-induced platelet aggregation in vitro; leaves open whether it prevents no-reflow during rotational atherectomy.
Structured PICO
Does abciximab reduce rotablation-induced platelet aggregation in platelet-rich plasma from healthy volunteers?
P
Population
Platelet-rich plasma (PRP) prepared from 28 healthy human volunteers
I
Intervention
Preincubation with abciximab (c7E3 Fab, anti-GP IIb/IIIa+alpha(v)beta3) prior to in vitro rotablation at various speeds (70000, 150000, and 180000 rpm)
C
Comparator
No antibody treatment or preincubation with 6D1 (anti-GP Ib) prior to rotablation
O
Outcome
Platelet aggregation (slope of aggregation)surrogate
Abciximab significantly inhibits platelet aggregation induced by high-speed rotablation in vitro, suggesting a potential mechanism to prevent the no-reflow phenomenon during rotational atherectomy.
Cite This Study
Williams et al. (1998) studied this question.